Global Myelodysplastic Syndromes (MDS) Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Myelodysplastic Syndromes (MDS) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Jan 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Myelodysplastic syndromes (MDS) Market, By Type (Myelodysplastic Syndrome with Unilineage Dysplasia, Myelodysplastic Syndrome with Multilineage Dysplasia, Myelodysplastic Syndrome with Ring Sideroblasts, Others), Therapeutic Class (Hypomethylating Agents, Immunomodulatory Drugs, Anti-anemics), Treatment (Supportive Therapy, Growth Factors, Chemotherapy, Stem Cell Transplant, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Myelodysplastic Syndromes (MDS) Market

Market Analysis and Insights Global Myelodysplastic Syndromes (MDS) Market

Myelodysplastic syndromes (MDS) market size is projected to grow at a compound annual growth rate of 6.85% over the forecast period of 2022 to 2029. Data Bridge Market Research report on myelodysplastic syndromes (MDS) market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.

Myelodysplastic syndromes (MDS) also commonly referred as preleukemia is basically a haematological condition under which the bone marrow is not able to make enough new blood cells. This can affect few or all three components of blood cells which collectively called as blood lineages. The different types of myelodysplastic syndromes are myelodysplastic syndrome with unilineage dysplasia, myelodysplastic syndrome with multilineage dysplasia, myelodysplastic syndrome with ring sideroblasts and others.

The high prevalence of cardiovascular disorders and adoption of sedentary life style across the globe is expected to accelerate the market growth in the forecast period of 2022 to 2029. In addition to this, the launches of drugs annually and improvement in treatment are some of the impacting factors will further carve the way for the growth of the market. The strong presence of pipeline drugs is also expected to boost the overall growth of the market. However, the factors such as limited revenue opportunities coupled with product recalls significantly are projected to restraint the market growth rate.

In addition, the technical advancements and high research and development investments on the development of novel treatments for MDS are likely to create various new opportunities that will impact this myelodysplastic syndromes (MDS) market growth in the forecast period of 2022 to 2029. On the flip side, the side effects associated with the medications also hampers the overall growth of the market, which is estimated to challenge the market’s growth.

This myelodysplastic syndromes (MDS) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the myelodysplastic syndromes (MDS) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Myelodysplastic Syndromes (MDS) Market Scope and Market Size

Myelodysplastic syndromes (MDS) market is segmented on the basis of types, therapeutic class, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of types, the global myelodysplastic syndromes (MDS) market is segmented into myelodysplastic syndrome with unilineage dysplasia, myelodysplastic syndrome with multilineage dysplasia, myelodysplastic syndrome with ring sideroblasts and others.
  • On the basis of therapeutic class, the global myelodysplastic syndromes (MDS) market is segmented into hypomethylating agents, immunomodulatory drugs and anti-anemics.
  • Based on treatment, the global myelodysplastic syndromes (MDS) market is segmented into supportive therapy, growth factors, chemotherapy, stem cell transplant and others.
  • The route of administration segment for global myelodysplastic syndromes (MDS) market is segmented into oral, injectable and others.
  • On the basis of end-users, the global myelodysplastic syndromes (MDS) market is segmented into hospitals, homecare, speciality centres and others.
  • On the basis of distribution channel, the global myelodysplastic syndromes (MDS) market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.

Myelodysplastic Syndromes (MDS) Market Country Level Analysis

Myelodysplastic syndromes (MDS) market is segmented on the basis of types, therapeutic class, treatment, route of administration, end-users and distribution channel.

The countries covered in the myelodysplastic syndromes (MDS) market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America leads the myelodysplastic syndromes (MDS) market due to the high demand of diseases specific treatment, rise in adoption of newer technologies, presence of refined healthcare expenditure and increased patient awareness level as well as high prevalence of myelodysplastic syndromes in this region. Europe region, on the other hand is expected to expand at a significant growth rate because of the presence of global marketed players in this region and growing cases of mental illness.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Myelodysplastic syndromes (MDS) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Myelodysplastic Syndromes (MDS) Market Share Analysis

Myelodysplastic syndromes (MDS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to myelodysplastic syndromes (MDS) market.

Some of the major players operating in the myelodysplastic syndromes (MDS) market report are Otsuka Holdings Co., Ltd., Lupin, Medtronic, Takeda Pharmaceutical Company Limited, Onconova Therapeutics, Helsinn Healthcare SA, Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited., MEI Pharma Inc., MTW Endoskopie Manufaktur, Aprea Therapeutics, Dr. Reddy's Laboratories Ltd, AbbVie Inc., Acceleron Pharma, Inc., Mylan N.V., Bristol-Myers Squibb Company, Eisai Co., Ltd., and LGM Pharma among others.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are the major data pointers of the Myelodysplastic Syndromes (MDS) Market.
The hospitals, homecare, speciality centres are the market applications of Myelodysplastic Syndromes (MDS) Market.
The high prevalence of cardiovascular disorders and adoption of sedentary life style across the globe are the growth drivers of the Myelodysplastic Syndromes (MDS) Market.
The factors on which the Myelodysplastic Syndromes (MDS) Market research is based are types, therapeutic class, treatment, route of administration, end-users and distribution channel.
The major companies in the Myelodysplastic Syndromes (MDS) Market areOtsuka Holdings Co., Ltd., Lupin, Medtronic, Takeda Pharmaceutical Company Limited, Onconova Therapeutics, Helsinn Healthcare SA, Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited., MEI Pharma Inc., MTW Endoskopie Manufaktur, Aprea Therapeutics, Dr. Reddy's Laboratories Ltd, AbbVie Inc., Acceleron Pharma, Inc., Mylan N.V., Bristol-Myers Squibb Company, Eisai Co